Dew, would it be outlandish to think that cirrhotics data would lead to ABBV/ENTA taking more market share than GILD if first to market since GILD data looks rather weak there?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.